Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Other Working Capital Changes (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Other Working Capital Changes for 3 consecutive years, with -$174046.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 420.18% to -$174046.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$74046.0 through Dec 2025, down 25.94% year-over-year, with the annual reading at -$74046.0 for FY2025, 1022.76% down from the prior year.
  • Other Working Capital Changes hit -$174046.0 in Q4 2025 for Mangoceuticals, down from $134845.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $283333.0 in Q2 2024 to a low of -$174046.0 in Q4 2025.
  • Historically, Other Working Capital Changes has averaged $18736.7 across 3 years, with a median of $2392.0 in 2023.
  • Biggest five-year swings in Other Working Capital Changes: soared 1218.75% in 2024 and later tumbled 420.18% in 2025.
  • Year by year, Other Working Capital Changes stood at -$14746.0 in 2023, then skyrocketed by 468.63% to $54358.0 in 2024, then crashed by 420.18% to -$174046.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for MGRX at -$174046.0 in Q4 2025, $134845.0 in Q3 2025, and -$17596.0 in Q2 2025.